Recombinant Research
Lymphoblastoid interferon may clear hepatitis B better than recombinant therapy
Published in Hepatitis Weekly, September 27th, 2004
"To compare the long-term effect of natural lymphoblastoid interferon-alpha (IFN-alpha nl) and recombinant IFN-alpha2a therapy in patients with chronic hepatitis B, 210 patients in two trials were followed-up for 1.1-15.5 years following the end of therapy," scientists in Taiwan report.
"They included 34 patients who received placebo (control), 67 treated with IFN-alpha nl (36 after prednisolone priming) and 109 treated with IFN-alpha2a (56 after prednisolone priming)," S.M. Lin and colleagues, Chang Gung University, Liver Research Unit described.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-09-27)
More Articles from Hepatitis Weekly
- Chronic Liver Disease
Silent hepatitis B does not alter hepatitis C-related liver disease - Environmental Health
Combined technologies detect hepatitis A virus in environmental samples - Immunology
Fine-needle aspiration biopsies predict how hepatitis C will respond to therapy - Liver Fibrosis
Hepatitis B virus X antigen activates fibrinogen gene expression - Antiviral Therapy
Chronic hepatitis C nonresponders are a challenge to clinical management - Business & Finance
Novo Nordisk A/S completes investment in biopharma company - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
